Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Dexmethylphenidate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Cingulate Therapeutics, LLC
Deal Size : Undisclosed
Deal Type : Agreement
Cingulate and Indegene Announce Joint Commercialization Agreement for Lead ADHD Candidate CTx-1301
Details : Under the agreement, Indegene will provide commercial support for Cingulate’s lead candidate CTx-1301 (dexmethylphenidate), a novel, investigational treatment being developed as a true, once-daily stimulant medication for attention deficit/hyperactivit...
Product Name : CTx-1301
Product Type : Controlled Substance
Upfront Cash : Undisclosed
March 13, 2023
Lead Product(s) : Dexmethylphenidate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Cingulate Therapeutics, LLC
Deal Size : Undisclosed
Deal Type : Agreement